US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US5770442A
(en)
*
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
DK1445322T4
(da)
|
1995-06-15 |
2012-09-03 |
Crucell Holland Bv |
Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi
|
SK95599A3
(en)
|
1997-01-17 |
2000-05-16 |
Rhone Poulenc Rorer Sa |
Adenoviral-vector-mediated gene transfer into medullary motor neurons
|
FR2761258B1
(fr)
*
|
1997-03-26 |
1999-06-11 |
Rhone Poulenc Rorer Sa |
Procede de stimulation de la regeneration nerveuse
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US7468181B2
(en)
*
|
2002-04-25 |
2008-12-23 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
WO2001036603A2
(en)
*
|
1999-11-17 |
2001-05-25 |
Avigen, Inc. |
Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
|
US7235233B2
(en)
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
CA2471812C
(en)
*
|
2001-12-21 |
2012-09-04 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery to motor neurons
|
US6998118B2
(en)
*
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
EP2019683B2
(en)
|
2006-04-25 |
2022-08-03 |
The Regents of The University of California |
Administration of growth factors for the treatment of cns disorders
|
PL2396038T3
(pl)
|
2009-02-12 |
2016-05-31 |
Curna Inc |
Leczenie chorób związanych z neurotropowym czynnikiem pochodzenia mózgowego (bdnf) poprzez zahamowanie naturalnego antysensownego transkryptu bdnf
|
CA2752239C
(en)
|
2009-02-12 |
2021-03-30 |
Opko Curna, Llc |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
CA2754749C
(en)
|
2009-03-04 |
2019-04-30 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
EP2427552B1
(en)
|
2009-05-06 |
2016-11-16 |
CuRNA, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CA2761152A1
(en)
|
2009-05-06 |
2010-11-11 |
Opko Curna, Llc |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
US8957037B2
(en)
|
2009-05-18 |
2015-02-17 |
Curna, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
EP2432882B1
(en)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
ES2618576T3
(es)
|
2009-05-28 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
|
ES2620960T3
(es)
|
2009-06-16 |
2017-06-30 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de colágeno mediante la inhibición de un transcrito antisentido natural a un gen de colágeno
|
EP2443238B1
(en)
|
2009-06-16 |
2017-03-22 |
CuRNA, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
US8859515B2
(en)
|
2009-06-24 |
2014-10-14 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
|
JP5907866B2
(ja)
|
2009-06-26 |
2016-04-26 |
クルナ・インコーポレーテッド |
ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
|
WO2011017516A2
(en)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
US9023822B2
(en)
|
2009-08-25 |
2015-05-05 |
Curna, Inc. |
Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
DK2516648T3
(en)
|
2009-12-23 |
2018-02-12 |
Curna Inc |
TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
|
EP2519634B1
(en)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
JP5993744B2
(ja)
|
2009-12-29 |
2016-09-14 |
カッパーアールエヌエー,インコーポレイテッド |
核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療
|
DK2521784T3
(en)
|
2010-01-04 |
2018-03-12 |
Curna Inc |
TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
EP3517613A1
(en)
|
2010-04-09 |
2019-07-31 |
CuRNA, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
KR101936011B1
(ko)
|
2010-05-03 |
2019-01-07 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
WO2011150005A2
(en)
|
2010-05-26 |
2011-12-01 |
Opko Curna Llc |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
ES2663598T3
(es)
|
2010-07-14 |
2018-04-16 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo de discos grandes (dlg) mediante la inhibición del transcrito antisentido natural a dlg
|
WO2012047956A2
(en)
|
2010-10-06 |
2012-04-12 |
Opko Curna Llc |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
KR101913232B1
(ko)
|
2010-10-27 |
2018-10-30 |
큐알엔에이, 인크. |
인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
|
US8987225B2
(en)
|
2010-11-23 |
2015-03-24 |
Curna, Inc. |
Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
|
EP2718439B1
(en)
|
2011-06-09 |
2017-08-09 |
CuRNA, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
CA2963288A1
(en)
|
2014-10-03 |
2016-04-07 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
SG11201802870RA
(en)
|
2015-10-09 |
2018-05-30 |
Univ Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
EP3389725B1
(en)
|
2015-12-14 |
2022-04-06 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of central nervous system diseases
|
EP3390636B1
(en)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of dravet syndrome
|
JP2019500345A
(ja)
|
2015-12-14 |
2019-01-10 |
コールド スプリング ハーバー ラボラトリー |
肝臓病の処置のための組成物および方法
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JP7054675B2
(ja)
|
2015-12-14 |
2022-04-14 |
コールド スプリング ハーバー ラボラトリー |
網膜色素変性症18と網膜色素変性症13の処置のための組成物と方法
|
JP2018538288A
(ja)
|
2015-12-14 |
2018-12-27 |
コールド スプリング ハーバー ラボラトリー |
アラジール症候群の処置のためのアンチセンスオリゴマー
|
EP3673080B1
(en)
|
2017-08-25 |
2023-10-18 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
US20230287410A1
(en)
|
2020-05-11 |
2023-09-14 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
EP4326873A1
(en)
|
2021-04-22 |
2024-02-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
WO2023178311A1
(en)
*
|
2022-03-18 |
2023-09-21 |
The University Of North Carolina At Chapel Hill |
Methods for treating disorders under hypothermia and compositions relating to the same
|